For example, inhibition of IL-6 by the first anti-IL-6 antibody, tocilizumab, has been shown to completely block TF-dependent thrombin generation in experimental endotoxemia [23, 96], and tocilizumab will be of special future interest as it has been approved for rheumatoid arthritis. The gene discussed is TF; the disease is rheumatoid arthritis.